Arthritis

Kevzara^B

(new active substance)

Medical ingredient:

Sarilumab

Indication:

Kevzara is used to treat adult patients with moderately to severely active rheumatoid arthritis (RA).

For more information, see the Regulatory Decision Summary.

Triamcinolone Hexacetonide Injectable Suspension

Medical ingredient:

Triamcinolone Hexacetonide

Indication:

Triamcinolone Hexacetonide Injectable Suspension is used in adults and adolescents to treat the symptoms of subacute and chronic inflammatory joint diseases including:

• rheumatoid arthritis
• Juvenile Idiopathic Arthritis (JIA)
• osteoarthritis and post-traumatic arthritis
• inflammation of the membrane that lines the joint (synovitis)
• inflammation or irritation of the tendon, a thick cord that attaches bone to muscle (tendinitis)
• inflammation or irritation of the bursa, the fluid filled sac located between tissues such as bone, muscle, tendons and skin that decreases rubbing and irritation (bursitis)
• inflammation of the tendons around an epicondyle, the end of a bone, often in the elbow (epicondylitis)

For more information, see the Regulatory Decision Summary.

Health Canada approved two new generic drugs for arthritis.

Erelzi^{B, O}

Medical ingredient:

Etanercept

Indication:

Erelzi is a medicine for treating people with moderate to severe forms of rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA). Erelzi is also for treating adults with a type of arthritis called ankylosing spondylitis (AS).

For more information, see the Regulatory Decision Summary.

Renflexis^{B, O}

Medical ingredient:

Infliximab

Indication:

Renflexis is a medicine that is used in people with moderate to severe rheumatoid arthritis (in combination with methotrexate) and ankylosing spondylitis. Renflexis is also used in people with moderate to severe plaque psoriasis. Renflexis is also used in people with active psoriatic arthritis. Renflexis is also used in adults, children and teenagers with moderate to severe Crohn's disease or with moderate to severe ulcerative colitis.

For more information, see the Regulatory Decision Summary.

Health Canada released one risk communication on arthritis.